---
document_datetime: 2025-04-09 10:43:37
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rasagiline-ratiopharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rasagiline-ratiopharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7627873
conversion_datetime: 2025-12-30 13:06:30.757184
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rasagiline ratiopharm

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a variation | 07/04/2025                          | N/A                                         | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000255892                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                           |            |         | PL               |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|------------------|
| Variation type IB / EMA/VR/0000244788 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted | 03/04/2025 | N/A N/A |                  |
| Article 61(3) / EMA/N/0000254937      | - Notification acc. Article 61(3) - Update of the labelling and package leaflet to align with the latest QRD template version                                                                                                                                                                                                                                                                                                                                     | 18/03/2025 |         | Labelling and PL |

<div style=\"page-break-after: always\"></div>

| 10.4 and to align some of the translations with the English product information in terms of EXP/Lot in compliance with Appendix IV. Furthermore, the package leaflet was updated with revised contact details of local representatives and the MAH took the opportunity to introduce minor editorial amendments to the package leaflet.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|